Evox and Takeda sign deal to collaborate on rare disease treatments
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
List view / Grid view
News
FDA and EMA offer updates on COVID-19 treatments and vaccines in development
The FDA and EMA have announced which COVID-19 treatments and vaccines are currently in development, as well as how they are supporting clinical trials.
Wearable patch device could provide an affordable insulin therapy for type 2 diabetics
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
J&J says clinical trials for COVID-19 vaccine candidate will begin by September
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
EMA warns consumers about falsified COVID-19 drugs from online pharmacies
The European Medicines Agency (EMA) has advised consumers on how to recognise registered online pharmacies so they can avoid falsified medications.
Stem cell therapy shows efficacy at treating COVID-19, finds study
Researchers in China administered COVID-19 patients with a mesenchymal stem cell therapy that demonstrated success at treating the condition.
Female directors are quicker to recall defective medicinal products, finds study
The presence of female directors makes boards more likely to report lower-severity defects and faster to recall products with high-severity problems, suggests research.
Study suggests Zolgensma will generate $2.5bn of global sales by 2025
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
EMA advises continued use of hypertension drugs during COVID-19 pandemic
The EMA has said that patients should continue to use angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), despite reports that these worsen COVID-19 infections.
Big pharma’s in-house manufacturing impacted by COVID-19 outbreak in China
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
Global trial to evaluate Kevzara® (sarilumab) as COVID-19 therapy initiated
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.
FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
Over 90 percent of medical marijuana in US contains high levels of THC, study finds
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
UK government calls for increased supply of COVID-19 testing kits
The UK government has reached out to the life sciences sector to ask potential suppliers of COVID-19 testing kits to get in contact.
